Part ofcoronavirus →

FEDERALhearing transcript

High Impact

Congressional Hearing on Emergent BioSolutions Vaccine Manufacturing Failures

Original title: EXAMINING EMERGENT BIOSOLUTIONS' FAILURE TO PROTECT PUBLIC HEALTH AND PUBLIC FUNDS

January 1, 2021

coronavirus public health government spending vaccine manufacturing oversight

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing addresses the loss of millions of COVID-19 vaccine doses and the oversight of $650 million in federal funds awarded to a private contractor for pandemic response.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Emergent BioSolutions, Inc.

The company is the subject of a congressional investigation regarding its manufacturing practices and use of federal funds.

General Public

The public experienced delays in vaccine availability due to the destruction of doses manufactured by the company.

What changed

Last recorded activity January 1, 2021.

What's next

Next step not available in the current record.

Summary

The House on the Coronavirus Crisis held a hearing to investigate reports that Emergent failed to maintain proper manufacturing standards, leading to the destruction of millions of COVID-19 vaccine doses. The hearing examined the company's use of nearly $650 million in federal taxpayer funds and its inability to meet production expectations.

Key Facts

The Trump administration awarded Emergent BioSolutions approximately $650 million in federal funds for vaccine manufacturing.
Millions of COVID-19 vaccine doses were destroyed due to contamination at Emergent facilities.
Additional millions of vaccine doses were held back for testing to ensure safety.
The subcommittee investigation cited failures in facility maintenance, staff training, and protocol adherence.
The hearing was held on May 19, 2021, by the Select Subcommittee on the Coronavirus Crisis.
The subcommittee released a staff memorandum detailing warnings the company received regarding manufacturing problems.

Frequently Asked Questions

Why were millions of vaccine doses destroyed?

According to the subcommittee, the doses were destroyed due to contamination resulting from failures to maintain facilities, train staff, and follow proper protocols.

Did this hearing question the safety of the COVID-19 vaccines currently in use?

No. The Chairman explicitly stated that the hearing was not about questioning the safety or efficacy of authorized vaccines, which he described as safe and effective.

Why It Matters

This hearing addresses the loss of millions of COVID-19 vaccine doses and the oversight of $650 million in federal funds awarded to a private contractor for pandemic response.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift80% confidence

Oversight of Pandemic Contracting

The document highlights a shift toward increased congressional scrutiny of private contractors receiving large-scale federal funding during the pandemic.

Emergent BioSolutions, Inc.Select Subcommittee on the Coronavirus Crisis

Connected Entities

personFaud El-Hibri“Executive Chairman of the Board of Directors at Emergent BioSolutions, Inc.”Map →

personRobert G. Kramer“President and CEO of Emergent BioSolutions, Inc.”Map →

personJames E. Clyburn“Chairman of the Select Subcommittee on the Coronavirus Crisis.”Map →

organizationEmergent BioSolutions, Inc.“The company under investigation for manufacturing failures and receipt of federa”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy75
Intensity of disagreement among stakeholders
Entertainment60
Compellingness for a non-policy-wonk reader
Buzz40
Current news / social attention level

Publisher tools